Ton Logtenberg, PhDPresident and CEO at Merus N.V.
Prof. Ton Logtenberg received his Ph.D. in Immunology from the University of Utrecht. In 1996, he was appointed Professor in Immunology-biotechnology and founded U-BiSys, a biotechnology company that merged with IntroGene to become the publicly-listed company Crucell. In 2006, Ton founded and became the CEO of Merus, a Nasdaq-listed biotechnology company focusing on human bispecific antibodies based on the full length IgG format for the treatment of cancer patients. Ton currently holds a chair in Entrepreneurship in the Life Sciences at Utrecht University.